Travere Therapeuticsinc Formerly Known As Retrophinwas Founded In February 2011 And Became Publicly Traded In December 2012The Company Rebranded In November 2020 To Focus On Its Mission Of Addressing Rare Diseasesparticularly In Nephrologyhepatologyand Metabolic Disordersit Is Headquartered In San Diegocalifornia Travere Therapeutics Markets Filsparisparsentan Which Is Designed To Reduce Proteinuria In Adults With Primary Immunoglobulin A Nephropathyiganat Risk Of Rapid Disease Progressionthe Company Is Also Developing Therapies For Other Conditionsincluding Sparsentan For Focal Segmental Glomerulosclerosisfsgsand Pegtibatinasetvt 058For Classical Homocystinuriahcu Travere Collaborates With Academic Institutions And Researchers To Advance Its Drug Development Effortstargeting Patients With Rare Kidneyliverand Metabolic Diseases
No conferences found for this company.
| Company Name | Retrophin Europe Ltd |
| Country |
Ireland
|
| Address | 2nd Floor Palmerston House Fenian Street Dublin 2 Ireland |
| Telephone | Login to View |
| Login to View |
